NasdaqGS - Nasdaq Real Time Price USD

AstraZeneca PLC (AZN)

Compare
78.31 +0.46 (+0.59%)
At close: 4:00 PM EDT
78.32 +0.01 (+0.01%)
After hours: 5:23 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
49,133,000.00
45,811,000.00
44,351,000.00
37,417,000.00
26,617,000.00
--
Cost of Revenue
8,804,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
--
Gross Profit
40,329,000.00
37,543,000.00
31,960,000.00
24,980,000.00
21,318,000.00
--
Operating Expense
30,751,000.00
28,821,000.00
27,448,000.00
25,119,000.00
17,402,000.00
--
Operating Income
9,578,000.00
8,722,000.00
4,512,000.00
-139,000.00
3,916,000.00
--
Net Non Operating Interest Income Expense
-1,279,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
--
Pretax Income
7,746,000.00
6,899,000.00
2,501,000.00
-265,000.00
3,916,000.00
--
Tax Provision
1,301,000.00
938,000.00
-792,000.00
-380,000.00
772,000.00
--
Net Income Common Stockholders
6,440,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
--
Diluted NI Available to Com Stockholders
6,440,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
--
Basic EPS
2.08
1.92
1.06
0.04
1.22
--
Diluted EPS
2.06
1.91
1.05
0.04
1.22
--
Basic Average Shares
3,098,000.00
3,098,000.00
3,096,000.00
2,836,000.00
2,624,000.00
--
Diluted Average Shares
3,124,000.00
3,124,000.00
3,120,000.00
2,854,000.00
2,626,000.00
--
Total Operating Income as Reported
9,049,000.00
8,193,000.00
3,757,000.00
1,056,000.00
5,162,000.00
--
Rent Expense Supplemental
--
301,000.00
268,000.00
262,000.00
228,000.00
--
Total Expenses
39,555,000.00
37,089,000.00
39,839,000.00
37,556,000.00
22,701,000.00
--
Net Income from Continuing & Discontinued Operation
6,440,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
--
Normalized Income
6,846,868.71
6,375,540.00
3,888,210.00
-852,710.00
2,192,424.92
--
Interest Income
371,000.00
301,000.00
81,000.00
43,000.00
83,000.00
--
Interest Expense
1,650,000.00
1,589,000.00
1,330,000.00
1,276,000.00
1,272,000.00
--
Net Interest Income
-1,279,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
--
EBIT
9,396,000.00
8,488,000.00
3,831,000.00
1,011,000.00
5,188,000.00
--
EBITDA
14,086,000.00
13,422,000.00
9,085,000.00
5,113,000.00
8,084,000.00
--
Reconciled Cost of Revenue
8,804,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
--
Reconciled Depreciation
4,690,000.00
4,934,000.00
5,254,000.00
4,102,000.00
2,896,000.00
--
Net Income from Continuing Operation Net Minority Interest
6,440,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
--
Total Unusual Items Excluding Goodwill
-489,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
--
Total Unusual Items
-489,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
--
Normalized EBITDA
14,575,000.00
13,911,000.00
9,826,000.00
3,922,000.00
6,834,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-82,131.29
-68,460.00
-140,790.00
226,290.00
246,424.92
--
12/31/2019 - 5/12/1993

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers